AdvanSource Announces Conference Call on February 18 at 2:30 PM Eastern For Third Quarter of Fiscal 2009.WILMINGTON, Mass. -- AdvanSource Biomaterials Corporation (NYSE NYSE See: New York Stock Exchange Alternext US: ASB ASB Asbestos ASB Arbeiter Samariter Bund (German medical help organisation) ASB Anti-Social Behaviour ASB Accounting Standards Board (UK FRC) ASB Aarhus School of Business ), a leading developer of advanced polymer materials for a broad range of medical devices, announced today that it will release its results for the third quarter of fiscal 2009 before the market opens on Wednesday, February 18, 2009. Following the release, the Company will host a conference call for investors at 2:30 p.m. ET (11:30 a.m. PT) to discuss its fiscal third quarter results as well as recent developments. The February 18 date is later than usual due to travel commitments for a major industry conference and expo in California during the prior week. Participants should dial-in (866) 206-7204 Conference ID# 1326033 or (703) 639-1114 outside the U.S. Please dial-in 10 minutes before the call is scheduled to begin. A replay of the call will be available for two weeks following the call at (888) 266-2081 ID# 1326033 and on the Company's website. About AdvanSource Biomaterials Corporation AdvanSource Biomaterials Corporation manufactures advanced polymer materials which provide critical characteristics in the design and development of medical devices. The Company's biomaterials are used in devices that are designed for treating a broad range of anatomical anatomical /ana·tom·i·cal/ (an?ah-tom´i-kal) pertaining to anatomy, or to the structure of an organism. an·a·tom·i·cal or an·a·tom·ic adj. 1. Concerned with anatomy. 2. sites and disease states. AdvanSource's business model leverages its proprietary materials science materials science Study of the properties of solid materials and how those properties are determined by the material's composition and structure, both macroscopic and microscopic. technology and manufacturing expertise in order to expand its product sales and royalty and license fee income. The Company is conducting a clinical trial for regulatory approval at two sites in Europe for its CardioPass[TM] synthetic coronary bypass coronary bypass Surgical treatment for coronary heart disease to relieve angina pectoris and prevent heart attacks. It became widely used in the 1960s. One or more blood vessels—usually an artery in the chest or a vein from the leg—are transplanted to create graft graft, in surgery: see transplantation, medical. graft In horticulture, the act of placing a portion of one plant (called a bud or scion) into or on a stem, root, or branch of another (called the stock) in such a way that a union forms and the . More information about AdvanSource is available at its website: www.advbiomaterials.com |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion